These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1321448)
1. Use of gamma-linolenic acid in the treatment of schizophrenia and tardive dyskinesia. Vaddadi KS Prostaglandins Leukot Essent Fatty Acids; 1992 May; 46(1):67-70. PubMed ID: 1321448 [TBL] [Abstract][Full Text] [Related]
2. The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism. Horrobin DF Prostaglandins Leukot Essent Fatty Acids; 1992 May; 46(1):71-7. PubMed ID: 1321449 [TBL] [Abstract][Full Text] [Related]
3. Essential fatty acid supplementation in tardive dyskinesia. Wolkin A; Jordan B; Peselow E; Rubinstein M; Rotrosen J Am J Psychiatry; 1986 Jul; 143(7):912-4. PubMed ID: 3013033 [TBL] [Abstract][Full Text] [Related]
9. [Significance and motivation of the clinical use of essential fatty acid derivatives, especially gamma-linolenic acid]. Bordoni A Clin Ter; 1990 Mar; 132(6):383-92. PubMed ID: 2158408 [TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Lee JG; Shin BS; Lee YC; Park SW; Kim YH Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029 [TBL] [Abstract][Full Text] [Related]
11. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report. Rizos EN; Chatziioannou S; Siafakas N; Douzenis A; Katsantoni E; Mandrapilia A; Bacalis S; Fotiadis C; Lykouras L Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1135-6. PubMed ID: 20460141 [No Abstract] [Full Text] [Related]
16. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106 [TBL] [Abstract][Full Text] [Related]
17. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405 [TBL] [Abstract][Full Text] [Related]
18. Baclofen in the treatment of tardive dyskinesia and schizophrenia. Simpson GM; Lee JH; Shrivastava RK; Branchey MH Psychopharmacol Bull; 1978 Apr; 14(2):16-8. PubMed ID: 349598 [No Abstract] [Full Text] [Related]
19. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan. Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630 [TBL] [Abstract][Full Text] [Related]
20. Effect of dietary alpha-linolenic acid on equine monocyte procoagulant activity and eicosanoid synthesis. Henry MM; Moore JN; Feldman EB; Fischer JK; Russell B Circ Shock; 1990 Nov; 32(3):173-88. PubMed ID: 1979759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]